A KRAS-variant as a biomarker of ovarian cancer risk

Note: KRAS has been studied in colorectal cancer impacting on treatment program/no indication if ovarian cancer/Lynch Syndrome patients were included

Conclusions: These findings strongly support the hypothesis that the KRAS-variant is a genetic marker of an increased risk of developing ovarian cancer, and suggests that the KRAS- variant may be a new biomarker of risk for HBOC families without other known genetic abnormalities. In addition, the KRAS-variant predicts for the most deadly ovarian cancers, which are likely the most important to prevent or catch early.